Mebeverine

Summary

Mebeverine (CHEMBL282121) is an approved small molecule (ATC A03AA04); indicated across 2 conditions including irritable bowel syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AA04
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 429.5 Da · C25H35NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL282121
Name	Mebeverine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4031
ATC	A03AA04
Molecular formula	C25H35NO5
Molecular weight	429.5
InChIKey	VYVKHNNGDFVQGA-UHFFFAOYSA-N

SMILES: CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC

IUPAC name: 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate

Also known as: Arluy, Mebeverina, Mebeverine, SID11112523, SID50100996, MEBEVERINE, mebeverine

Parent form; salt/anhydrous children: CHEMBL1446650

Patent coverage: 757 distinct patent families (3,027 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyrotropin receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 22 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2D6	7.6	Potency	25.1	nM	CHEMBL_ACT_4998447
CYP2D6	7.6	AC50	25.12	nM	CHEMBL_ACT_5988693
SLC6A4	6.43	AC50	370	nM	CHEMBL_ACT_25151001
CHRM3	6.22	AC50	600	nM	CHEMBL_ACT_25137355
SLC6A3	6.16	AC50	700	nM	CHEMBL_ACT_25124633
CYP3A4	6.1	Potency	794.3	nM	CHEMBL_ACT_4985951
CYP3A4	6.1	Potency	794.3	nM	CHEMBL_ACT_5054976
CYP3A4	6.1	AC50	794.3	nM	CHEMBL_ACT_6049060
KCNH2	6.02	AC50	950	nM	CHEMBL_ACT_25118855
CHRM1	5.96	AC50	1100	nM	CHEMBL_ACT_25136157
ADRA2C	5.68	AC50	2100	nM	CHEMBL_ACT_25148575
SLC6A2	5.6	AC50	2500	nM	CHEMBL_ACT_25145676
ADRA2A	5.55	AC50	2800	nM	CHEMBL_ACT_25220549
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3915491
OPRK1	5.02	AC50	9500	nM	CHEMBL_ACT_25130056

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00934973	PHASE4	COMPLETED	Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)
NCT05867550	PHASE4	COMPLETED	To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
NCT04217733	PHASE3	RECRUITING	Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
NCT05175131	PHASE3	COMPLETED	Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
NCT02260154	Not specified	COMPLETED	Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).